Photocure‘s patent covers a method for photodynamic therapy (PDT) in treating non-muscle invasive bladder cancer (NMIBC). The method involves instilling a composition of hexyl 5-ALA ester (HAL) into the bladder and exposing it to blue light, enhancing treatment efficacy post-transurethral resection. GlobalData’s report on Photocure gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
According to GlobalData’s company profile on Photocure, Photodynamic cancer therapy drugs was a key innovation area identified from patents. Photocure's grant share as of June 2024 was 48%. Grant share is based on the ratio of number of grants to total number of patents.
The granted patent US11980772B2 outlines a method for photodynamic therapy (PDT) as an adjuvant treatment for non-muscle invasive bladder cancer (NMIBC). This method is specifically designed for patients who are undergoing or have undergone transurethral resection of NMIBC. The procedure involves instilling an aqueous solution containing hexyl 5-ALA ester (HAL) or its pharmaceutically acceptable salts into the bladder at concentrations ranging from 0.1% to 5%. Following the instillation, the bladder is exposed to blue light with a fluence rate between 1.5 to 12.5 mW/cm², delivering a light dose of 0.2 to 15.0 J/cm². The claims further specify variations in fluence rates and light doses, including the use of white light in conjunction with blue light, and the potential for the method to replace or supplement existing therapies such as chemotherapy, immunotherapy, or Bacillus Calmette-Guerin (BCG) treatment.
Additional claims detail the specific parameters for light exposure, including the use of a blue-light cystoscope as the light source and the duration of exposure, which ranges from 2 to 20 minutes. The composition of the HAL solution is also described, including its formulation in an aqueous buffer with a pH between 4.5 and 7.5. The patent emphasizes the method's applicability in patients who are refractory to BCG treatment, highlighting its potential as a novel therapeutic option in the management of NMIBC. Overall, the claims provide a comprehensive framework for the implementation of this photodynamic therapy method, focusing on its efficacy and adaptability in clinical settings.
To know more about GlobalData’s detailed insights on Photocure, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies
